Invivyd (IVVD) EBIT (2021 - 2026)
Invivyd's (IVVD) quarterly EBIT came in at -$12.6 million in Q4 2025, up 34.71% YoY from -$9.3 million in Q4 2024, and down 13.9% on a QoQ basis from -$11.0 million in Q3 2025.
Invivyd (IVVD) EBIT (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of EBIT data on file, last reported at -$12.6 million in Q4 2025.
- Quarterly EBIT rose 34.71% year-over-year to -$12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$55.6 million (up 68.59% YoY) and the FY2025 annual result came in at -$55.6 million, up 68.59% from the prior year.
- EBIT eased to -$12.6 million in Q4 2025, from -$11.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$11.0 million in Q3 2025 to a low of -$100.7 million in Q1 2022.
- A 5-year average of -$46.0 million and a median of -$46.7 million in 2022 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT plunged 160.25% — and 2025, when it soared 82.31%.
- Tracing IVVD's EBIT over 5 years: stood at -$83.1 million in 2021, then soared by 41.98% to -$48.2 million in 2022, then tumbled by 59.2% to -$76.8 million in 2023, then soared by 74.95% to -$19.2 million in 2024, then soared by 34.71% to -$12.6 million in 2025.
- The last three EBIT figures came in at -$12.6 million (Q4 2025), -$11.0 million (Q3 2025), and -$15.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | -45.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.82 Mn |
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -16.92 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -62.31 Mn |
| Jun 30, 2024 | -49.25 Mn |
| Mar 31, 2024 | -46.09 Mn |
| Dec 31, 2023 | -76.75 Mn |
| Sep 30, 2023 | -43.06 Mn |
| Jun 30, 2023 | -53.88 Mn |
| Mar 31, 2023 | -39.07 Mn |
| Dec 31, 2022 | -48.21 Mn |
| Sep 30, 2022 | -47.33 Mn |
| Jun 30, 2022 | -51.75 Mn |
| Mar 31, 2022 | -100.74 Mn |
| Dec 31, 2021 | -83.09 Mn |
| Sep 30, 2021 | -60.42 Mn |
| Jun 30, 2021 | -44.69 Mn |